Maxigen Biotech Inc. (TPE:1783)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
39.40
+1.30 (3.41%)
Apr 29, 2026, 1:30 PM CST
-5.97%
Market Cap 3.53B
Revenue (ttm) 811.56M
Net Income (ttm) 265.31M
Shares Out 89.68M
EPS (ttm) 2.94
PE Ratio 13.40
Forward PE n/a
Dividend 0.83 (2.18%)
Ex-Dividend Date Sep 5, 2025
Volume 212,323
Average Volume 132,945
Open 38.60
Previous Close 38.10
Day's Range 38.60 - 40.00
52-Week Range 37.80 - 48.85
Beta 0.31
RSI 35.79
Earnings Date Mar 20, 2026

About Maxigen Biotech

Maxigen Biotech Inc. researches, develops, produces, and sells implantable medical devices in Taiwan, America, Europe, rest of Asia, and internationally. It operates through two segments, Biomedical Products and Consumer Products. The company provides biomedical materials, such as collagen and bone supplements; beauty and skincare products; and medical devices for ophthalmology, otolaryngology, dental, surgical, orthopedics, electronic instructions for use, and medical aesthetics, as well as engages in collagen purification activities. It also ... [Read more]

Sector Healthcare
Founded 1998
Country Taiwan
Stock Exchange Taiwan Stock Exchange
Ticker Symbol 1783
Full Company Profile

Financial Performance

In 2025, Maxigen Biotech's revenue was 811.56 million, an increase of 19.23% compared to the previous year's 680.65 million. Earnings were 265.31 million, an increase of 39.52%.

Financial Statements

News

There is no news available yet.